Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide

In the REWIND trial, dulaglutide reduced cardiovascular (CV) risk versus placebo in patients with type 2 diabetes in both the “established CV disease” (CVD) and “CV risk factor” subgroups. The SUSTAIN 6 and PIONEER 6 trials of semaglutide used different criteria for established CVD from those used i...

Descripción completa

Detalles Bibliográficos
Autores principales: Verma, Subodh, Fainberg, Udi, Husain, Mansoor, Rasmussen, Søren, Rydén, Lars, Ripa, Maria Sejersten, Buse, John B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251906/
https://www.ncbi.nlm.nih.gov/pubmed/33606902
http://dx.doi.org/10.1111/dom.14360

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251906/
https://www.ncbi.nlm.nih.gov/pubmed/33606902
http://dx.doi.org/10.1111/dom.14360

Ejemplares similares